Home・Aktien・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Open

13.24 2.08

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

12.88

Max

13.46

Schlüsselkennzahlen
By Trading Economics
Einkommen	-1.4M -14M
EPS	-0.15
Angestellte	37
EBITDA	312K -12M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+142.33% upside

Dividenden
By Acuity
Nächstes Ergebnis	6. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-261M 1.1B
Vorheriger Eröffnungskurs	11.16
Vorheriger Schlusskurs	13.24

Corvus Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

29. Juli 2026, 23:56 UTC

LifeVantage Corp shares are trading lower in after-market hours. No specific news was identified to explain this movement.

29. Juli 2026, 23:56 UTC

Zoom Video Communications Inc is trading lower in after-market hours. Broader market uncertainty regarding future interest rate decisions may be influencing investor sentiment.

29. Juli 2026, 23:56 UTC

Harrow Inc shares are lower in after-market hours amid broad weakness in the Pharmaceuticals sub-sector, with the price significantly below its 20-day moving average.

29. Juli 2026, 23:56 UTC

Sprinklr Inc. shares are higher in after-market trading, continuing an upward trajectory amid positive market sentiment following the Federal Reserve's expected interest rate decision.

29. Juli 2026, 23:56 UTC

Becton Dickinson and Co shares are higher in after-market hours, maintaining momentum from Wednesday's close amid uncertainty over future interest rate decisions.

29. Juli 2026, 23:56 UTC

News

Industrial Logistics Properties Trust shares declined after second-quarter results missed expectations, reporting a loss of -$0.22 per share and revenue of $114.12 million.

29. Juli 2026, 23:56 UTC

Archer-Daniels-Midland shares are higher in after-hours trading, reflecting stability despite no specific news to explain the movement.

29. Juli 2026, 23:56 UTC

Correlated Moves

Corsair Gaming Inc shares are higher in after-market trading, supported by positive sentiment and strength in small-cap stocks, including the Russell 2000 Index.

29. Juli 2026, 23:56 UTC

Standard BioTools Inc. shares traded roughly flat during after-market hours, showing little change since Wednesday's close amid a stable trading range.

29. Juli 2026, 23:56 UTC

Axon Enterprise Inc. shares advanced slightly in after-market trading, reflecting routine performance, though they remain below their 20-day moving average.

29. Juli 2026, 23:56 UTC

Correlated Moves

Pentair PLC shares are higher in after-market trading, reflecting a positive trend in the Russell 2000 Index and steady interest rates from the Federal Reserve.

29. Juli 2026, 23:56 UTC

Correlated Moves

Cloudflare Inc. trades higher in after-market hours, reflecting strength near its one-month range. The move aligns with trends in the cybersecurity sector.

29. Juli 2026, 23:56 UTC

Clorox Co. shares declined in after-market trading, despite recovering from earlier lows. The stock remains above its 20-day moving average.

29. Juli 2026, 23:56 UTC

Correlated Moves

Okta Inc shares rose in after-market trading, reflecting positive momentum in the cybersecurity sector and broader market sentiment regarding steady interest rates.

29. Juli 2026, 23:56 UTC

Correlated Moves

DR Horton shares are higher in after-market trading, supported by a rising Russell 2000 Index and stable interest rate expectations from the Federal Reserve.

29. Juli 2026, 23:56 UTC

Trade Desk Inc. shares are lower in after-market trading, despite remaining above their 20-day moving average after four consecutive higher daily closes.

29. Juli 2026, 23:56 UTC

Powell Industries shares are higher in after-market trading, despite a generally flat cumulative return and ongoing uncertainty regarding interest rates.

29. Juli 2026, 23:56 UTC

News

Adobe shares rose after-market, reaching about $263.62. Elevated options volume and a lower put/call ratio reflect bullish sentiment.

29. Juli 2026, 23:56 UTC

Correlated Moves

Energy Fuels Inc shares are higher in after-market hours, reflecting a correlation with Cameco Corp's recent gains amid broader market uncertainty over interest rates.

29. Juli 2026, 23:56 UTC

AeroVironment Inc shares are higher in after-market trading, reflecting a modest gain since Wednesday's close amid cautious market sentiment regarding interest rate expectations.

29. Juli 2026, 23:56 UTC

Campbell Soup Co. shares traded higher in after-market hours, remaining above the 20-day moving average and near the upper end of their one-month range.

29. Juli 2026, 23:56 UTC

Correlated Moves

ETF Constituents

Macro News

Financial Select Sector SPDR Fund trades higher in after-market hours, supported by gains from key holdings and a rise in the Dow Jones Index.

29. Juli 2026, 23:56 UTC

Alcoa Corp shares advanced modestly in after-market trading following Wednesday's close, amid uncertainty over future interest rate changes.

29. Juli 2026, 23:56 UTC

Correlated Moves

Lennar Corp sees a modest increase in after-market trading, supported by positive market sentiment and a rise in the Russell 2000 Index.

29. Juli 2026, 23:56 UTC

Alphabet Inc. shares declined in after-market trading, reflecting a cumulative drop since Wednesday's close and remaining below the 20-day moving average.

29. Juli 2026, 23:56 UTC

Social Media

Alphabet Inc shares declined in after-market trading, remaining below their 20-day moving average amid ongoing market uncertainty about future rate hikes.

29. Juli 2026, 23:56 UTC

Macro Event

Cardano is higher today amid expectations of a future Fed rate hike, despite ongoing geopolitical tensions and easing inflation data.

29. Juli 2026, 23:56 UTC

News

Logitech International SA's quarterly report filing has led to shares trading higher in after-market hours, reflecting increased investor interest.

29. Juli 2026, 23:56 UTC

Macro News

ETF Constituents

Utilities Select Sector SPDR Fund trades higher in after-market hours, buoyed by strong returns from NextEra Energy and Entergy amid rising geopolitical tensions.

29. Juli 2026, 23:56 UTC

Viridian Therapeutics Inc shares are lower in after-market trading, with no specific news identified to explain the decline. Broader market uncertainty persists.

Peer-Vergleich

Kursveränderung

Corvus Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

142.33% Vorteil

12-Monats-Prognose

Durchschnitt 31.6 USD 142.33%

Hoch 40 USD

Tief 27 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Corvus Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

5 ratings

Buy

Halten

Sell

Basierend auf 5 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Corvus Pharmaceuticals Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.